Recombinant Human EEF2, N-His

Description of Recombinant Human EEF2, N-His

Introduction

Recombinant Human EEF2, N-His is a protein that has been genetically engineered to mimic the function of the naturally occurring human EEF2 protein. This protein plays a crucial role in protein synthesis, making it a potential target for drug development. In this article, we will discuss the structure, activity, and potential applications of Recombinant Human EEF2, N-His as a drug target.

Structure of Recombinant Human EEF2, N-His

Recombinant Human EEF2, N-His is a 102 kDa protein composed of 853 amino acids. It is a member of the elongation factor family and is highly conserved across species. The protein contains several functional domains, including the GTP-binding domain, the ribosome-binding domain, and the ATP-binding domain. These domains are essential for the protein’s activity in protein synthesis.

Activity of this protein

The primary function of Recombinant Human EEF2, N-His is to facilitate the elongation step of protein synthesis. This process involves the movement of the ribosome along the mRNA strand, adding amino acids to the growing polypeptide chain. EEF2 plays a crucial role in this process by promoting the translocation of the ribosome from one codon to the next. This movement is powered by the hydrolysis of GTP, which is facilitated by the GTP-binding domain of EEF2.

In addition to its role in protein synthesis, EEF2 has also been shown to have other cellular functions. It has been implicated in cell growth and survival, as well as in the regulation of gene expression. These activities make EEF2 a potential target for drug development in various diseases.

Application as a Drug Target

The essential role of EEF2 in protein synthesis and other cellular processes makes it a potential target for drug development. Dysregulation of EEF2 has been linked to various diseases, including cancer, neurodegenerative disorders, and viral infections. By targeting EEF2, it may be possible to modulate protein synthesis and other cellular activities, leading to potential therapeutic benefits.

One potential application of Recombinant Human EEF2, N-His as a drug target is in cancer treatment. Cancer cells have an increased demand for protein synthesis to support their rapid growth and proliferation. Targeting EEF2 could potentially slow down or inhibit protein synthesis in cancer cells, leading to their death. This approach has shown promising results in preclinical studies and is currently being investigated in clinical trials.

In addition to cancer, EEF2 has also been implicated in neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease. These diseases are characterized by abnormal protein accumulation in the brain, and targeting EEF2 could potentially help regulate protein synthesis and reduce the buildup of these abnormal proteins.

Furthermore, EEF2 has also been found to play a role in viral infections. Viruses rely on the host cell’s protein synthesis machinery to replicate and produce viral proteins. By targeting EEF2, it may be possible to disrupt this process and inhibit viral replication, making it a potential strategy for antiviral drug development.

Conclusion

In summary, Recombinant Human EEF2, N-His is a genetically engineered protein that mimics the function of the naturally occurring EEF2 protein. It plays a crucial role in protein synthesis and has been implicated in various cellular processes, making it a potential target for drug development. Its potential applications in cancer, neurodegenerative disorders, and viral infections make it a promising candidate for future research and development.